Australia's Lumos Diagnostics hits 3-1/2-year high on sales jump

Lumos Diagnostics Holdings

23/10/2025 04:21

** Shares of Lumos Diagnostics LDX.AX rise as much as 12.8% to A$0.265, highest level since May 12, 2022

** Q1 product revenue rises four-fold to $1.2 million, helped by increasing adoption of FebriDx across the U.S.

** FebriDx is co's rapid point of care test to help differentiate between bacterial and non-bacterial acute respiratory infections

** YTD, shares have risen more than seven-fold in value

 (Reporting by Nichiket Sunil in Bengaluru)

 ((Nichiket.Sunil@thomsonreuters.com))